ArticleMetabolic brain disease2026
Neuroprotective and cognitive-enhancing effects of γ-Oryzanol in bile duct ligation-induced hepatic encephalopathy in rats.
Article in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Hepatic encephalopathy (HE) is a complex neuropsychiatric syndrome characterized by a spectrum of symptoms ranging from mild cognitive and motor disturbances to severe coma. γ-Oryzanol (ORY), a natural compound derived from rice bran, has demonstrated potential to enhance memory and cognitive function in preclinical studies. This study investigated the neuroprotective and cognitive-enhancing effects of γ-oryzanol in a rat model of HE induced by bile duct ligation (BDL). Male Wistar rats underwent BDL surgery and received either γ-oryzanol (100 mg/kg) or vehicle via oral gavage for subchronic 28 days. Four experimental groups were included: sham-operated, sham + ORY, BDL, and BDL + ORY. Cognitive function was assessed using the Novel Object Recognition (NOR) test and Y-maze. Blood samples were analyzed for oxidative stress markers (antioxidant status, lipid peroxidation, thiol levels), liver function markers (bilirubin, albumin, AST, ALT, ALP, LDH), and prefrontal cortex tissues were examined histologically. BDL induction significantly impaired cognitive performance and increased oxidative stress and neuronal damage in the prefrontal cortex. γ-Oryzanol treatment effectively restored cognitive function, reduced oxidative stress, and attenuated neuronal damage without significantly altering liver enzyme levels. These findings suggest that γ-oryzanol exerts neuroprotective effects in HE possibly through antioxidant-related pathways, although this mechanism was not consistently supported by all oxidative stress markers. The protective effects appeared largely independent of major liver function improvement.
Indexed as
Identifiers
42678464What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.